Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr AeRang Kim
Children's National Hospital, Washington, DC, USA
Dr AeRang Kim is a professor of paediatrics with tenure and the director of clinical research in the Division of Oncology and Solid Tumors attending at Children’s National Hospital in Washington, DC. read more
Dr Kim’s research focuses on novel therapeutics for paediatric solid tumours, sarcomas and NF1-associated tumours, in particular malignant peripheral nerve sheath tumours (MPNST).
Dr Kim serves as the MPNST disease committee chair for the Department of Defense Clinical Trials Consortium. She is the co-director of the Focused Ultrasound Foundation Center of Excellence at the Children’s National Hospital. With collaborators and federal funding support, Dr AeRang Kim has been able to develop and lead early-phase trials of novel combination therapeutics for paediatric patients with solid tumours, including sarcoma. She also serves as the institutional principal investigator at Children’s National Hospital for the Children’s Oncology Group, Pediatric Early Phase Clinical Trials Network with the major goal of conducting early-phase trials in children with cancer to identify and develop new agents for children and adolescents.
Dr AeRang Kim has no financial interests/relationships or affiliations to disclose in relation to this activity.
Dr Rebecca Brown
University of Alabama School of Medicine, Birmingham, AL, USA
Dr Rebecca Brown, MD, PhD is the director of the neurofibromatosis programme at the University of Alabama at Birmingham (UAB). read more
Dr Brown is a board-certified neuro-oncologist and neurologist who specializes in neurofibromatosis (NF) and schwannomatosis (SWN; including NF2-related schwannomatosis), and related genetic nervous system tumour conditions. She earned her PhD from the Institute for Neuroscience at University of Texas (UT), Austin in 2007 studying the multi-generational effects of endocrine disrupting pollutants on female health. She subsequently completed a post-doctoral fellowship at the Center for Strategic and Innovative Technologies at UT, Austin, investigating the effects of sleep deprivation on cognition and physical performance. Dr Brown completed her MD at UT Southwestern in Dallas, TX, in 2013, where she studied NF1. She subsequently completed a neurology residency at Mount Sinai and a neuro-oncology fellowship at Memorial Sloan Kettering Cancer Center, specializing in NF1. She developed and served as the director of the NF and SWN clinic at Mount Sinai before being recruited to UAB. Dr Brown’s primary research interest is the development of novel pharmacotherapies for NF and SWN-related tumours.
Dr Rebecca Brown discloses: Independent contractor fees from Pasithea, Inc. Advisory Board or panel fees from Neurovigil. Consultancy fees from Guidepoint.
Dr Kaleb Yohay
NYU Langone Health, New York, NY, USA
Dr Kaleb Yohay, MD, is professor of neurology and paediatrics (clinical) at New York University (NYU) and director of the Division of Child Neurology and the Comprehensive Neurofibromatosis Center, which is recognized as recognized as one of the nation’s foremost for neurofibromatosis. read more
Dr Yohay received his medical degree from the University of Vermont in 1993, and completed a residency in paediatrics and neurology at Johns Hopkins Hospital in Baltimore, MD. During his tenure at Johns Hopkins, he established and directed the Johns Hopkins Neurofibromatosis Center. He moved home to New York City in 2007, and joined the faculty at Weill Cornell Medical Center, and served as attending physician at New York Presbyterian and Memorial Sloan Kettering Cancer Center. Since 2014, Dr Yohay has been on the faculty at NYU Grossman School of Medicine.
Dr Yohay’s clinical practice is exclusively focused on treating individuals with NF1, NF2, and schwannomatosis. He is keenly invested in the development of best practice for the screening, treatment, and provision of age-appropriate guidance for those affected by neurofibromatosis. Dr Yohay has dedicated his career to pioneering new treatments for neuro-oncological and neuro-genetic conditions. This includes spearheading a gene therapy trial aimed at treating late infantile neuronal ceroid lipofuscinosis, innovating drug delivery techniques for pontine glioma, and leading clinical trials focused on neurofibromatosis. He is currently involved in national and international clinical trial consortia for NF1, NF2 and schwannomatosis. He serves as the chair of the programmatic panel for the Department of Defense Neurofibromatosis Research Program. Beyond his research interests, Dr Yohay is committed to the development and education of future NF-focused clinicians.
Dr Kaleb Yohay discloses: Advisory board or panel fees from Alexion. Stock/shareholder (self-managed) with Infixion Bioscience.
